LungHealth MedTech Secures Over RMB 100 Million in Series B Funding to Advance Natural Orifice Transluminal Endoscopic Surgery Robotics

Recently, Langhe Medical, a Chinese technology company focused on the research and development of robotic systems for natural orifice flexible endoscopic surgery, announced that it has completed its Series B financing round, raising over RMB 100 million. The round was led by Yinglian Health Fund, with continued participation from existing and new investors, including Qianhou Yingkang Fund under Gangyue Capital, Xie Li Investment, and Taikun Fund.

This round of financing aims to expand the company’s leading advantage in natural orifice surgical robots and minimally invasive, precision diagnosis and treatment interventions for pulmonary conditions, accelerate the clinical and commercial progress of its related product portfolio, and provide disruptive platform-based minimally invasive diagnostic and therapeutic solutions for various diseases, including lung cancer.

Dr. Ma Jiajun, Founder and CEO of Langhe Medical, stated“We extend our sincere gratitude to both new and existing shareholders for their trust and support in Longhe Medical. Longhe Medical will remain steadfast in its innovation path integrating medicine and engineering, focusing on the research, development, and application of minimally invasive, precision diagnostic and therapeutic technologies via natural orifices. By achieving coverage across multiple indications and integrating diverse technologies, we aim to create next-generation surgical solutions via natural orifices, continue to advance medical technology, and contribute to the Healthy China 2030 initiative.”

Yinglian Health Fund stated“Lung cancer is one of the most prevalent cancers in China, and patients often face challenges with difficult and highly invasive biopsies. Surgical robots will provide more precise solutions. Internationally, giants such as Johnson & Johnson and Intuitive Surgical are actively deploying in the field of transbronchial flexible surgical robots, with their respective products experiencing rapid sales growth over the past few years. Longhe’s development of transbronchial surgical robots is at the forefront in China, and its extensive product portfolio in respiratory intervention will offer better solutions for Chinese doctors and patients as these products are successively launched.”

Xie Li Investment stated“Longhe Medical operates in the high-growth sector of minimally invasive and non-invasive pulmonary diagnosis and treatment, an area characterized by substantial unmet clinical needs and broad development prospects. Since Xeli Investment acquired a stake in Longhe during its Series A financing round, the company has experienced rapid business growth, achieving significant results through its forward-looking layout in the field of flexible surgical robots. Xeli Investment maintains strong confidence in Longhe’s management team, having continuously increased its investment in previous financing rounds and further doubling down in this current round. We are confident that Longhe will become the leader in natural orifice transluminal endoscopic diagnosis and treatment technologies for pulmonary conditions in China.”

Project Leader, Taikun Fundindicate“In recent years, the incidence of lung cancer and respiratory diseases has remained high with a trend toward affecting younger populations. Traditional diagnostic and therapeutic approaches have certain limitations, resulting in substantial unmet clinical needs. New products, therapies, and technologies, represented by flexible robotics, are becoming increasingly mature, with their safety and efficacy clinically validated, demonstrating significant market potential. Based on its visualization- and intelligence-enabled navigation technology platform and flexible robotics technology platform, Langhe Medical has developed a diversified portfolio of diagnostic and therapeutic product lines, providing clinicians and patients with comprehensive, integrated technological and product solutions.”

Longhe Medical is a leading Chinese medical surgical robotics technology company, founded in 2015 in the Zero Bay Global Innovation and Entrepreneurship Cluster in Shanghai. The company has made comprehensive strides in next-generation minimally invasive interventional technologies for oncology, including natural orifice transluminal endoscopic surgery (NOTES) robots and beyond-line-of-sight precise lung navigation systems, achieving significant results. Longhe Medical has received numerous national and provincial honors, such as being named one of China’s Top 100 Innovative Growth Enterprises, a Potential Unicorn Enterprise of Jiangsu Province, and an Enterprise under the Jiangsu Province Double Innovation Plan. The company is also CE-certified by the European Union and certified under China’s Quality Management System standards. Having completed multiple rounds of financing, Longhe Medical has raised a cumulative total exceeding hundreds of millions of RMB. Its shareholders include prominent professional healthcare investment institutions such as Guoke Investment (under the Chinese Academy of Sciences), Yinglian Health, Xieli Investment, Taiyu Investment, Shanlan Capital, Yuegang Capital, and Taikun Fund. The company has established its management, marketing, and R&D headquarters in Shanghai, while its 5,000-square-meter GMP-compliant production base, pilot-scale R&D facility, and product exhibition center are located in the Xitaihu International Medical Device Industrial Park in Changzhou, Jiangsu Province.

Yinglian Health Fund was established in early 2019, with cornerstone investors drawn from leading pharmaceutical companies in the industry. Research-driven, the fund deeply explores global investment opportunities in cutting-edge innovative drugs, medical technologies, and devices. It co-incubates companies alongside top scientists, Principal Investigators (PIs), and clinical translation teams to address the challenge of translating source innovation from concept to reality (from 0 to 1).

Xieli Investment was established in 2012, focusing on early-to-mid-stage venture capital. Its investment focus primarily includes mass consumption, biomedicine and healthcare, high-end equipment manufacturing, and new materials. To date, it has invested in more than 70 companies, with over 20 investments in the biomedicine and healthcare sector. Adhering long-term to the philosophy of “not just an investor, but a caring entrepreneurial partner,” Xieli Investment provides systematic and professional post-investment management, accompanies companies throughout their growth journey, and consistently creates value for its Limited Partners (LPs).

Hong Kong-Guangdong Capital (IFSC), established in 2014, is a private equity investment firm specializing in biotechnology and life sciences (Fund Registration No.: P1065723). Guided by the investment philosophy of “value investing driven by basic science,” the firm identifies “scientific entrepreneurs” and focuses on investment opportunities in leading companies within fields such as synthetic biology, neuroscience, cell and gene therapy, bio-agriculture, and reproductive and ophthalmic healthcare.

Taikun Fund is a biomedical industry fund jointly established by Tigermed, Hangzhou Capital, and Hangzhou Gaoke Sci-Tech Innovation. Leveraging Tigermed’s industrial layout as a clinical CRO and aligning with the strategic development of Hangzhou’s pharmaceutical industry, the fund operates on market-oriented principles. Focusing on the life and health industry, it prioritizes investments in innovative medical devices, biopharmaceuticals, healthcare services, healthcare informatics, digital therapeutics, intelligent manufacturing, and nutritional health companies.